Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

Article Dermatology

Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials

Boni Elewski et al.

Summary: The efficacy of brodalumab in treating nail or scalp psoriasis was evaluated in three phase 3 studies. The results showed that brodalumab led to scalp clearance within 12 weeks and improvements in nail psoriasis within 52 weeks.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma

Caterina Lanna et al.

Summary: This study evaluated the impact of psoriasis on different body sites on the quality of life of patients and observed changes in quality of life during treatment. The results showed that itching acts as a mediator between the extension of psoriasis and its impact on quality of life, and nail psoriasis plays a predominant role in affecting the quality of life of patients.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Treatment of Nail Psoriasis

Martin Kassir et al.

Summary: Nail psoriasis has a negative impact on patients' quality of life, limiting their household chores, professional activities, and social interactions. Treatment is often overlooked and takes a long time to observe clinical improvement, which is also met with poor compliance. This review focuses on various treatment options for nail psoriasis.

JOURNAL OF DRUGS IN DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP)

A. David Burden et al.

Summary: This study aimed to understand key symptoms of generalized pustular psoriasis (GPP) and confirm the relevance and content validity of the Psoriasis Symptom Scale (PSS) in GPP. Literature review, clinical expert interviews, individual patient interviews, and a patient workshop were conducted. The study found that the PSS was well understood by patients and the symptoms included in the instrument were most frequently reported, important, and relevant to GPP.

DERMATOLOGY AND THERAPY (2022)

添加到收藏夹

Review Dermatology

Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies

Jensen Yeung et al.

Summary: The IL-17 signalling pathway is a significant target for treating plaque psoriasis, but it also increases the risk of fungal infections, specifically Candida albicans. It is crucial for patients and physicians on IL-17 biologics to understand how to manage these infections.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2022)

添加到收藏夹

Review Biology

Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness

Alin Codrut Nicolescu et al.

Summary: The severity evaluation of psoriasis in difficult-to-treat areas is a major challenge. There is controversy surrounding whether these areas should be evaluated differently. This review proposes solutions such as using special scores or adding correction factors to assess the severity of these areas within the existing scores.

LIFE-BASEL (2022)

添加到收藏夹

Review Dermatology

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis

Alan Menter et al.

Summary: Psoriatic involvement in specific areas such as nails, palms and soles, and scalp has a significant negative impact on quality of life. Although there is evidence for the efficacy of biologics in overall skin clearance for moderate-to-severe plaque psoriasis, more large-scale, randomized, placebo-controlled clinical studies are needed for psoriasis with nail, palmoplantar, and scalp involvement. Additionally, biologic failure due to drug ineffectiveness is common in patients who do not respond well to treatment or become intolerant. Brodalumab, a fully human IL-17 receptor A antagonist, has shown high rates of skin clearance in difficult-to-treat psoriasis.

DERMATOLOGY AND THERAPY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases

Fumi Miyagawa

Summary: Targeted biologic agents have had a significant impact on the treatment of immune-mediated inflammatory diseases. While they can greatly improve clinical symptoms, they also come with adverse reactions, including paradoxical reactions. Their efficacy in targeting specific cytokines and the presence of paradoxical reactions have helped researchers understand the underlying molecular pathways of these diseases.

BIOMEDICINES (2022)

添加到收藏夹

Article Health Care Sciences & Services

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

Linda Davidson et al.

Summary: There is a significant increase in the risk of candidiasis during Th17 inhibitor therapy, particularly for oropharyngeal, esophageal, and cutaneous candidiasis.

LANCET REGIONAL HEALTH-EUROPE (2022)

添加到收藏夹

Article Dermatology

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and-3

R. B. Warren et al.

Summary: Modern biologics can achieve complete skin clearance in 30-45% of psoriasis patients. This study compared the effectiveness of brodalumab and ustekinumab in achieving PASI 90 and 100 responses, finding that brodalumab resulted in significantly higher levels of skin clearance, longer sustained response, and greater cumulative treatment benefit compared to ustekinumab. Additionally, there was a significant positive association between PASI response level and health-related quality of life.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Dermatology

Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drive psoriasis-related inflammatory pathways

M. A. X. Tollenaere et al.

Summary: Multiple IL-17 ligands signaling through IL-17RA are overexpressed in psoriasis skin, inducing similar inflammatory pathways related to the disease. Brodalumab, as opposed to ixekizumab, can normalize gene expression responses induced by the combination of IL-17A, IL-17F, IL-17A/F, and IL-17C in human keratinocytes.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors

Georgios Kokolakis et al.

Summary: This study analyzed the efficacy of brodalumab versus ustekinumab in psoriasis patients with aggravating lifestyle risk factors and found that brodalumab achieved higher levels of complete skin clearance and quality of life compared to ustekinumab.

DERMATOLOGY AND THERAPY (2021)

添加到收藏夹

Review Dermatology

Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options

Alan Menter et al.

Summary: Pustular psoriasis is a rare form of psoriasis that poses clinical challenges for dermatologists. It presents with pustules and erythema, with two distinct subtypes. Treatment is often based on existing therapies, but there are limitations and challenges in managing the condition.

DERMATOLOGY AND THERAPY (2021)

添加到收藏夹

Letter Dermatology

Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors

Jensen Yeung et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis

Nikolai Loft et al.

Summary: This study demonstrates that treatment with brodalumab can be effective and well-tolerated in patients with previous treatment failure of an IL-17A inhibitor. Targeting cytokine levels may be associated with treatment response.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy

M. Galluzzo et al.

Summary: Real-life study on 90 patients with moderate-to-severe psoriasis treated with brodalumab showed that after 48 weeks, 92.2% of patients achieved a PASI score of <3. This suggests that brodalumab is effective and safe in treating patients with moderate-to-severe chronic psoriasis in a real-world setting.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

添加到收藏夹

Article Rheumatology

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

Philip J. Mease et al.

Summary: The study demonstrated that brodalumab significantly improved symptoms and was well tolerated in patients with PsA compared to placebo.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Dermatology

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials

S. Hsu et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Article Dermatology

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial

Luis Puig et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

添加到收藏夹

Review Dermatology

Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis

A. Egeberg et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Article Dermatology

Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)

K. Papp et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Article Dermatology

Comparison of Biologics and Oral Treatments for Plaque Psoriasis A Meta-analysis

April W. Armstrong et al.

JAMA DERMATOLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events

Amy Kunchok et al.

JAMA NEUROLOGY (2020)

添加到收藏夹

Review Dermatology

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics

Alan Menter et al.

DERMATOLOGY AND THERAPY (2020)

添加到收藏夹

Letter Dermatology

Recurrent erythrodermic psoriasis and polycythemia successfully treated with brodalumab

Nicoletta Bernardini et al.

DERMATOLOGIC THERAPY (2020)

添加到收藏夹

Review Cell Biology

Re-Examining the Role of TNF in MS Pathogenesis and Therapy

Diego Fresegna et al.

CELLS (2020)

添加到收藏夹

Article Dermatology

15908 Long-term efficacy and safety of brodalumab in patients with or without metabolic syndrome

Bruce Strober et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

添加到收藏夹

Article Dermatology

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations

A. Nast et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Review Allergy

The influence of body weight of patients with chronic plaque psoriasis on biological treatment response

Anna Kisielnicka et al.

POSTEPY DERMATOLOGII I ALERGOLOGII (2020)

添加到收藏夹

Review Dermatology

Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis

A. Mourad et al.

BRITISH JOURNAL OF DERMATOLOGY (2019)

添加到收藏夹

Letter Dermatology

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed

Grace Kimmel et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

添加到收藏夹

Article Dermatology

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials

R. G. Langley et al.

BRITISH JOURNAL OF DERMATOLOGY (2019)

添加到收藏夹

Review Dermatology

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review

Andreas Pinter et al.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2019)

添加到收藏夹

Editorial Material Dermatology

The multidimensional burden of psoriasis

P. Gisondi

BRITISH JOURNAL OF DERMATOLOGY (2018)

添加到收藏夹

Review Dermatology

Prevalence of genital psoriasis in patients with psoriasis

Kim A. P. Meeuwis et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2018)

添加到收藏夹

Review Dermatology

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Laura Sawyer et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2018)

添加到收藏夹

Article Dermatology

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

Kim A. Papp et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

添加到收藏夹

Article Dermatology

Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials

A. B. Gottlieb et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)

添加到收藏夹

Article Dermatology

Manifestations and Management of Difficult-to-Treat Psoriasis

Lakshi M. Aldredge et al.

JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION (2018)

添加到收藏夹

Article Dermatology

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study

K. Yamasaki et al.

BRITISH JOURNAL OF DERMATOLOGY (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Treatment Approaches to Moderate to Severe Psoriasis

Paolo Gisondi et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

添加到收藏夹

Article Dermatology

Improvement of nail psoriasis with brodalumab in phase 3 trials

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

添加到收藏夹

Letter Dermatology

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)

Andrew Blauvelt et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

添加到收藏夹

Article Dermatology

Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis

P. Gisondi et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

添加到收藏夹

Review Chemistry, Medicinal

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy

Michael Roman et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2017)

添加到收藏夹

Review Dermatology

Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis

Nilendu Sarma

INDIAN JOURNAL OF DERMATOLOGY (2017)

添加到收藏夹

Review Dermatology

Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

Girish S. Naik et al.

DERMATOLOGY (2017)

添加到收藏夹

Review Dermatology

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management

D. M. Saunte et al.

BRITISH JOURNAL OF DERMATOLOGY (2017)

添加到收藏夹

Article Dermatology

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

K. A. Papp et al.

BRITISH JOURNAL OF DERMATOLOGY (2016)

添加到收藏夹

Article Dermatology

Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis

Kim Papp et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Psoriasis

Wolf-Henning Boehncke et al.

LANCET (2015)

添加到收藏夹

Article Medicine, General & Internal

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

M. Lebwohl et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Dermatology

Treatment of Nail Psoriasis Best Practice Recommendations From the Medical Board of the National Psoriasis Foundation

Jeffrey J. Crowley et al.

JAMA DERMATOLOGY (2015)

添加到收藏夹

Review Dermatology

Nail psoriasis: a review of the literature

Karen Regina Rosso Schons et al.

ANAIS BRASILEIROS DE DERMATOLOGIA (2014)

添加到收藏夹

Article Immunology

Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody

Chris B. Russell et al.

JOURNAL OF IMMUNOLOGY (2014)

添加到收藏夹

Review Medicine, General & Internal

Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases

Emanuele Sinagra et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2013)

添加到收藏夹

Review Dermatology

The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings

David A. Martin et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)

添加到收藏夹

Letter Dermatology

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial

Kim A. Papp et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)

添加到收藏夹

Review Oncology

Consensus-based standards for best supportive care in clinical trials in advanced cancer

S. Yousuf Zafar et al.

LANCET ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis

Kim A. Papp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Critical Care Medicine

American College of Chest Physicians Consensus Statement on the Management of Dyspnea in Patients With Advanced Lung or Heart Disease

Donald A. Mahler et al.

CHEST (2010)

添加到收藏夹

Article Dermatology

Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis

Luigi Naldi et al.

DERMATOLOGY (2008)

添加到收藏夹

Article Rheumatology

Recommendations for musculoskeletal ultrasonography by rheumatologists: Setting global standards for best practice by expert consensus

AK Brown et al.

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2005)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial

ES Chung et al.

CIRCULATION (2003)

添加到收藏夹

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

相关参考文献

导出引文

分享论文